Gilead CEO on remdesivir: manufacturing, pricing for coronavirus drug - Business Insider

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 50 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 23%
  • Publisher: 51%

Canada News News

Canada Canada Latest News,Canada Canada Headlines

Gilead plans to spend up to $1 billion to ramp up manufacturing of its coronavirus treatment, but execs dodged Wall Street's questions about turning a profit

Join BI PrimeThe California biotech giant Gilead Sciences is planning to spend up to $1 billion to ramp up production of itsThe manufacturing ambitions come before the antiviral drug is approved by any health regulators for use in COVID-19, the disease caused by the coronavirus.

The ultimate size of the investment will depend on how the drug's data and the pandemic evolve, said Andrew Dickinson, Gilead's chief financial officer. Through the end of March, Gilead had spent about $50 million on remdesivir, without knowing whether or not it worked. Looking beyond the immediate term, Gilead executives declined to say how they'll set a price for the pill, which is now the frontrunner to be the first effective coronavirus treatment. Hospitalized patients who got remdesivir recovered 31% faster than a group taking placebo, the US National Institutes of Health found in a clinical trial.

SVB Leerink biotech analyst Geoff Porges, for instance, referenced the profit margins Gilead has made selling medicines for other infectious diseases like HIV and Hepatitis C."I don't think there is a precedent for this," O'Day replied, saying a market for a COVID-19 treatment will be unique and different from these other diseases.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Big pharma sux.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 729. in CA

Canada Canada Latest News, Canada Canada Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Coronavirus treatment: Gilead says positive data on remdesivir coming - Business InsiderOne of the most promising coronavirus treatment candidates succeeded in a late-stage trial in COVID-19 patients, Gilead said Wednesday.
Source: BusinessInsider - 🏆 729. / 51 Read more »

Tesla's Elon Musk doesn't behave like any other CEO in the business - Business InsiderEveryone has to accept that Tesla is worth $150 billion precisely because Elon Musk doesn't behave like any other CEO in the business High on something? Doesn’t mean he gets to have an effect on government decisions Musk has his heart & soul invested in his businesses. Look at it from that point of view. 👀
Source: BusinessInsider - 🏆 729. / 51 Read more »

Tesla's Elon Musk doesn't behave like any other CEO in the business - Business InsiderEveryone has to accept that Tesla is worth $150 billion precisely because Elon Musk doesn't behave like any other CEO in the business Get off his 🥜 Don’t take drugs kiddies! Cause he post memes no he’s just like the rest
Source: BusinessInsider - 🏆 729. / 51 Read more »

Billionaire Bill Ackman has 'enormous respect' for Tesla CEO Elon Musk - Business InsiderBillionaire investor Bill Ackman has 'enormous respect' for Tesla chief Elon Musk, but isn't a fan of his tweets What more is there to Elon than his tweets?
Source: BusinessInsider - 🏆 729. / 51 Read more »

Barclays' CEO says crowded offices could be 'a thing of the past' - Business InsiderAcross Wall Street, banks are rethinking how to safely return workers to offices which could look radically different in a post-pandemic world.
Source: BusinessInsider - 🏆 729. / 51 Read more »

Man Group CEO Luke Ellis says many employees will be working from home - Business InsiderMany financial services firms have been pleasantly surprised with how effective work-from-home policies have been during the coronavirus pandemic. The new Normal.. so long NYC BIGRENT
Source: BusinessInsider - 🏆 729. / 51 Read more »